Latest Clinical Services News

Emyria’s new treatment-resistant depression program shows statistically significant symptom improvements in a small initial cohort, expanding its mental health therapy offerings beyond PTSD.

Emyria has trained its first cohort of 31 clinicians in New South Wales, paving the way for its inaugural Sydney Empax clinic at Matilda Nepean, scheduled to open in Q3 2026.

Emyria Limited is progressing its national network of psychedelic-assisted therapy clinics, reporting durable patient outcomes, expanding funding sources, and benefiting from regulatory changes that broaden therapist eligibility.

Green Cross Health lifted net profit by 28% to NZD 20.4 million in FY26, driven by stronger medical funding and pharmacy revenue growth, while preparing to launch a new Primary Health Organisation.

Doctor Care Anywhere has snapped up the GLP-1 and medicated weight-loss business of Outcome Diagnostics and MedicSpot for £850,000, adding £5.3 million in trailing revenue and expanding its direct-to-consumer footprint in the UK.

Resonance Health upgrades its FY26 underlying EBITDA guidance to $2.6 million, driven by operational efficiencies and growth in its Software-as-Medical Devices segment, despite a slight revenue timing delay.

Emyria Limited reported $1.2 million in revenue for the March quarter, driven by insurer-funded clinics and strong clinical outcomes in PTSD treatment. The company is advancing its national clinic rollout, including new sites in Victoria and New South Wales, while launching a global partnership program targeting international drug sponsors.

Emyria reported $1.2 million revenue for Q1 2026 driven by insurer-funded clinics and expanded its Empax network across multiple states. It launched a Global Partnership Program targeting international drug sponsors, leveraging its clinical infrastructure amid growing global interest in psychedelic therapies.

Mayfield Childcare reported FY25 revenue growth driven by acquisitions but faced EBITDA decline due to occupancy and integration issues. Embark Education’s takeover bid adds a new dimension to the company’s strategic outlook.

Emyria Limited has reported a significant 136% increase in revenue to $1.55 million for the half-year ended December 2025, driven by its expanding Empax clinic network and insurer-funded treatments across Australia. Despite this growth, the company posted a $2.37 million net loss, reflecting investments in scaling operations and infrastructure.

Emyria has secured its first Empax clinic in Victoria, marking a significant step in its multi-state expansion and validating its scalable, reimbursed national mental health platform.

Mach7 Technologies reports a pivotal first quarter for FY26, marked by the initial go-live of a major U.S. Veterans Health Administration contract, leadership changes, and a strategic business reset.